EFIR yields 2000000.00% · ABBV yields 3.12%● Live data
📍 EFIR pulled ahead of the other in Year 1
Combined, EFIR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EFIR + ABBV for your $10,000?
EGPI Firecreek, Inc., an independent oil and gas company, engages in the exploration, development, and exploitation of crude oil and natural gas properties primarily in the United States. The company focuses on the oil and gas projects located in the Permian Basin areas of Texas, and surrounding states and regions in the United States for activities related to oil and gas production, and related business and other opportunities. It holds 50% working interests and corresponding 32% net revenue interests in oil and gas leases and reserves located in Callahan, Stephens, and Shakelford counties in west central Texas; and 75% working interests in the J.B. Tubb Leasehold Estate/Amoco Crawar field located in the Ward County in Texas. The company also offers oilfield services for drill site preparation to clear and lay pipelines for operators; and services to maintain lease roads, set power poles, and clean up oilfield spills. In addition, it engages in the sale, design/build, integration, and installation of thermal solar systems for residential and commercial sites. The company was formerly known as Energy Producers Inc. and changed its name to EGPI Firecreek, Inc. in October 2004. The company is based in Paradise Valley, Arizona.
Full EFIR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.